Recent chatter on X about Absci Corporation (ABSI) has been notably active following the company's announcement of a $50 million public offering, which triggered a sharp decline in its stock price. Many users have voiced concerns over the potential dilution of shares, especially since the offering was priced below market levels, leading to heated debates about the long-term impact on investor confidence. The unusually high trading volume during this period has only intensified the scrutiny of the company’s financial strategy.
Adding to the discussion, Absci’s expanded collaboration with Almirall on AI-driven drug discovery for dermatology targets has sparked fresh interest among X users. Some have highlighted the potential for significant milestone payments—up to $650 million across programs—as a positive counterbalance to the offering’s fallout, while others remain cautious about execution risks in such innovative fields. This mix of skepticism and optimism keeps the conversation dynamic and closely watched.
Note: This discussion summary was generated from an AI condensation of post data.
Absci Corporation Insider Trading Activity
Absci Corporation insiders have traded $ABSI stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
- ANDREAS BUSCH (Chief Innovation Officer) purchased 50,000 shares for an estimated $152,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Absci Corporation Hedge Fund Activity
We have seen 72 institutional investors add shares of Absci Corporation stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 4,873,904 shares (+36.1%) to their portfolio in Q1 2025, for an estimated $12,233,499
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,307,698 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,792,321
- FRED ALGER MANAGEMENT, LLC removed 2,211,391 shares (-34.0%) from their portfolio in Q1 2025, for an estimated $5,550,591
- BANK OF AMERICA CORP /DE/ added 1,475,554 shares (+1673.0%) to their portfolio in Q1 2025, for an estimated $3,703,640
- UBS GROUP AG added 1,349,062 shares (+188.9%) to their portfolio in Q1 2025, for an estimated $3,386,145
- MARSHALL WACE, LLP removed 1,151,846 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,891,133
- MILLENNIUM MANAGEMENT LLC added 1,049,900 shares (+4162.0%) to their portfolio in Q1 2025, for an estimated $2,635,249
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Absci Corporation Analyst Ratings
Wall Street analysts have issued reports on $ABSI in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 07/28/2025
- Needham issued a "Buy" rating on 05/14/2025
- Keybanc issued a "Overweight" rating on 04/16/2025
- Guggenheim issued a "Buy" rating on 03/20/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/19/2025
To track analyst ratings and price targets for Absci Corporation, check out Quiver Quantitative's $ABSI forecast page.
Absci Corporation Price Targets
Multiple analysts have issued price targets for $ABSI recently. We have seen 5 analysts offer price targets for $ABSI in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Vikram Purohit from Morgan Stanley set a target price of $6.4 on 07/28/2025
- Gil Blum from Needham set a target price of $9.0 on 05/14/2025
- Scott Schoenhaus from Keybanc set a target price of $9.0 on 04/16/2025
- Vamil Divan from Guggenheim set a target price of $10.0 on 03/20/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $7.0 on 03/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
